1
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Integrating radiomics into clinical trial design.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          In radiomics, quantitative features that describe phenotypic tumor characteristics are derived from radiographic images. Because radiomics generates information from routine medical images, it is a powerful way to non-invasively examine the spatial and temporal heterogeneity of disease, and thus has potential to significantly impact clinical trial design, execution, and ultimately patient care. The aim of this review article is to discuss how radiomics may address some of the current challenges in clinical randomized control trials, and the difficulties of integrating robust and repeatable radiomics analysis into trial design. Each step of the radiomics process, including image acquisition and reconstruction, image segmentation, feature extraction, and computational analysis, requires extensive standardization in order to be successfully incorporated into clinical trials and inform clinical decision making. By addressing these challenges, the potential of radiomics may be realized.

          Related collections

          Author and article information

          Journal
          Q J Nucl Med Mol Imaging
          The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of...
          Edizioni Minerva Medica
          1827-1936
          1824-4785
          Dec 2019
          : 63
          : 4
          Affiliations
          [1 ] Department of Medical Education, University of Michigan School of Medicine, Ann Arbor, MI, USA.
          [2 ] Michigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI, USA.
          [3 ] Department of Radiation Oncology, University of Michigan School of Medicine, Ann Arbor, MI, USA.
          [4 ] University of Michigan Rogel Cancer Center, University of Michigan, Ann Arbor, MI, USA.
          [5 ] Department of Nuclear Medicine, Poitiers University Hospital, Poitiers, France.
          [6 ] Department of Radiation Oncology, University of Michigan School of Medicine, Ann Arbor, MI, USA - ielnaqa@med.umich.edu.
          Article
          S1824-4785.19.03217-5
          10.23736/S1824-4785.19.03217-5
          31527581
          7ef8e56f-1873-48c9-8a58-1b44f4005295
          History

          Comments

          Comment on this article